Background Neoadjuvant chemotherapy (NAC) is standard for many females with breast
cancer (FBC). The efficacy of NAC in male breast cancer (MaBC) is unclear. The aim of this …

Background Neoadjuvant chemotherapy (NAC) downstages breast cancer and provides
prognostic information. Males with breast cancer are known to receive less treatment overall …

Background Male breast cancer (MBC) accounts for 1% of all breast cancers and there is a
paucity of data on factors impacting the treatment strategies and outcomes. We sought to …

Background Male breast cancer (MBC) is often diagnosed at a later stage and with a more
unfavorable tumor-to-breast ratio compared to women, prompting lower rates of breast …

Background Male breast cancer (BC) is a kind of rare tumour. There were few researches
concerning the effect of chemotherapy for it. The purpose of this study is to estimate the …

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant
chemotherapy in the treatment of male breast cancer patients has not been determined. The …

Aim: To assess whether prognostic factors in male (MBC) and female (FBC) breast cancer
have similar impact on survival. Patients and Methods: Charts for men and women …

Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for
breast cancer among black women and women who are overweight or obese, but this may …

Purpose Breast cancer in men accounts for approximately 1% of all breast cancers. Breast
cancer trials have routinely excluded men. The aim of this analysis was to determine the …

Background and purpose Due to the rarity of male breast cancer (male BC), no consensus
has been reached regarding the most appropriate curative treatment strategy. The objective …